Literature DB >> 17511846

Irreversible motor impairment in young addicts--ephedrone, manganism or both?

K Sikk1, P Taba, S Haldre, J Bergquist, D Nyholm, G Zjablov, T Asser, S-M Aquilonius.   

Abstract

BACKGROUND: Parkinsonian syndrome related to intravenous use of a "designer" psychostimulant, derived from pseudoephedrine using potassium permanganate as the oxidant, has been observed in drug addicts in Estonia.
OBJECTIVE: To describe the symptomatology of four young patients, history of drug administration and chemical analysis of a drug batch.
METHODS: Mental and motor function and quality of life were scored and ephedrone was analyzed using electrospray mass spectrometry. Manganese content of the final synthetic mixture was analyzed using Inductively Coupled Plasma-Atomic Emission Spectrometry.
RESULTS: None of the four cases scored below the dementia threshold in MMSE, while other ratings (UPDRS, H&Y, PDQ-39) corresponded to disabilities seen in relatively advanced Parkinson's disease. The ephedrone yield of the reaction was approximately 44% and the mixture was found to contain 0.6 g/l of manganese.
CONCLUSIONS: The cases were exposed to extreme manganese load. Their symptomatology is probably identical to manganism. The role of ephedrone is presently unknown. Physicians must be aware of early signs of manganism in patients within social risk groups.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17511846     DOI: 10.1111/j.1600-0404.2007.00818.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  23 in total

Review 1.  Role of manganese in neurodegenerative diseases.

Authors:  Aaron B Bowman; Gunnar F Kwakye; Elena Herrero Hernández; Michael Aschner
Journal:  J Trace Elem Med Biol       Date:  2011-10-01       Impact factor: 3.849

2.  White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome.

Authors:  Ainars Stepens; Charlotte Jane Stagg; Ardis Platkajis; Marie-Hélène Boudrias; Heidi Johansen-Berg; Michael Donaghy
Journal:  Brain       Date:  2010-10-29       Impact factor: 13.501

Review 3.  Manganese and its role in Parkinson's disease: from transport to neuropathology.

Authors:  Michael Aschner; Keith M Erikson; Elena Herrero Hernández; Elena Herrero Hernández; Ronald Tjalkens
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

Review 4.  Substance of abuse and movement disorders: complex interactions and comorbidities.

Authors:  Andres Deik; Rachel Saunders-Pullman; Marta San Luciano
Journal:  Curr Drug Abuse Rev       Date:  2012-09

5.  Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism.

Authors:  Atbin Djamshidian; Yanosh Sanotsky; Yuriy Matviyenko; Sean S O'Sullivan; Stephen Sharman; Marianna Selikhova; Ludmyla Fedoryshyn; Yuriy Filts; Jenny Bearn; Andrew J Lees; Bruno B Averbeck
Journal:  Addiction       Date:  2013-02-11       Impact factor: 6.526

6.  Increased APLP1 expression and neurodegeneration in the frontal cortex of manganese-exposed non-human primates.

Authors:  Tomás R Guilarte; Neal C Burton; Tatyana Verina; Vinaykumar V Prabhu; Kevin G Becker; Tore Syversen; Jay S Schneider
Journal:  J Neurochem       Date:  2008-02-13       Impact factor: 5.372

Review 7.  Manganese and Parkinson's disease: a critical review and new findings.

Authors:  Tomás R Guilarte
Journal:  Environ Health Perspect       Date:  2010-04-19       Impact factor: 9.031

8.  Manganese-Induced Parkinsonism due to Ephedrone Abuse.

Authors:  Katrin Sikk; Sulev Haldre; Sten-Magnus Aquilonius; Pille Taba
Journal:  Parkinsons Dis       Date:  2011-02-17

9.  Manganese exposure among smelting workers: blood manganese-iron ratio as a novel tool for manganese exposure assessment.

Authors:  Dallas M Cowan; Qiyuan Fan; Yan Zou; Xiujuan Shi; Jian Chen; Michael Aschner; Frank S Rosenthal; Wei Zheng
Journal:  Biomarkers       Date:  2009-02       Impact factor: 2.658

Review 10.  Manganese neurotoxicity: lessons learned from longitudinal studies in nonhuman primates.

Authors:  Neal C Burton; Tomás R Guilarte
Journal:  Environ Health Perspect       Date:  2008-10-03       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.